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013.01.00Abstract Aim of the work: To evaluate frequency and causes of discontinuation of methotrexate
(MTX) in a group of Egyptian patients and to identify factors that may increase the incidence of its
discontinuation.
Patients and methods: One hundred and ﬁfty seven rheumatoid arthritis (RA) patients with dis-
ease duration of at least one year, using or were using methotrexate, were included in this study. All
patients were subjected to full history taking including the cause of discontinuation of methotrexate,
full detailed clinical examination, laboratory assessment, X-ray hands and assessment of disease
activity score (28 joints) (DAS 28) for all RA patients. Patients were divided into two groups
according to the current status of MTX use, to identify factors which may increase the incidence
of MTX discontinuation.
Results: Forty six (29.3%) of the patients stopped MTX due to different causes, hepatic and gas-
trointestinal side effects were the most common causes of discontinuation, representing together
69.5% of causes of discontinuation. We found signiﬁcant statistical difference between the two
groups regarding disease duration, erythrocyte sedimentation rate (ESR), corticosteroid and non
steroidal-anti-inﬂammatory drug (NSAID) use.
Conclusion: MTX is a safe and effective drug for RA patients and usually well tolerated, how-
ever the use of NSAIDs and corticosteroid may be associated with increased risk of discontinuation
of methotrexate especially in patients with long standing disease.
 2013 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
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31. Introduction
Rheumatoid arthritis (RA) is a common, chronic, inﬂamma-
tory condition causing systemic illness and pain, swelling and
destruction of the joints [1]. It affects about 0.5–1% of the
population worldwide and is associated with signiﬁcant disor-
dering of physical function and decrease of quality of life. The
main aim of treatment of early RA should now be to achievection and hosting by Elsevier B.V.Open access under CC BY-NC-ND license.
Table 1 Laboratory features of our patients.
Range Mean ± SD
Hemoglobin (g%) 8–15.8 11.76 ± 1.43
Platelet (thousands/mm3) 118–541 304.52 ± 84.08
Creatinine (mg/dl) 0.3–1.6 0.83 ± 0.23
ESR (mm/ ﬁrst hour) 9–125 50.67 ± 24.17
TLC (thousands/mm3) 3.3–17.3 7.19 ± 2.43
ALT (U/L) 4–131 21.58 ± 23.70
Random blood sugar (mg/dl) 67–359 107.61 ± 36.03
ESR: Erthrocyte sedimentation rate, TLC: Total leucocytic count,
ALT: Alanine aminotransferase.
54 B.K. El-Zorkany et al.clinical remission, in order to prevent structural damage and
physical disability [2].
MTX is the most commonly used disease-modifying
anti-rheumatic drug (DMARD) for the treatment of RA [3].
It became recognized as the single most effective agent for
the treatment of RA in North America in the 1980s and in
Europe in the 1990s, and is widely acknowledged to be the
cornerstone of treatment of patients with RA [4]. MTX is
known to be a potent anti-inﬂammatory and immunosuppres-
sant agent that acts by decreasing cell proliferation, increasing
adenosine release, and inhibiting enzymes of folate metabolism
[5]. MTX also modiﬁes the expression of cellular adhesion
molecules, alters production of cytokines, and has effects on
humoral responses, and bone formation, and deposition [6].
The safety proﬁle of MTX has been studied over 25 years
with very few clinically important adverse events in the weekly
low-doses used for RA treatment. MTX courses show some of
the longest continuation rates reported in clinical medicine,
due to both effectiveness and safety. The safety proﬁle of
MTX indicates that it is among the safest of any mediation
used for the treatment of any arthritis [7]. MTX has a well-
deﬁned toxicity proﬁle and physicians should monitor patients
for gastrointestinal, hepatic, and pulmonary toxicity, bone
marrow suppression and stomatitis [8]. Most adverse effects
of methotrexate are mild and do not lead to discontinuation
of the medication, some toxicities of methotrexate (stomatitis,
nausea, bone marrow depression) are dose dependent, seem to
be related to folate deﬁciency, and respond to folate replace-
ment. Other toxicities seem to be idiosyncratic allergic and in
most cases require discontinuation of methotrexate (e.g. Pneu-
monitis). Still other toxicities, such as liver ﬁbrosis and cirrho-
sis, seem to be multifactorial and may depend on the presence
of concomitant risk factors, total dose and frequency of
administration [9].
Thus this study aim is to evaluate frequency and to identify
factors which may increase the incidence of methotrexate dis-
continuation in a group of Egyptian patients.
2. Patients and methods
This study included 157 rheumatoid arthritis patients accord-
ing to the revised ACR classiﬁcation criteria for RA [10]. Pa-
tients were attending Rheumatology department, Faculty of
Medicine, Cairo University Hospitals and private Rheumatol-
ogy center. Patients were taken consecutively provided that
they satisfy the following inclusion criteria:
1- Disease duration of at least one year.
2- Used or still using Methotrexate.
All patients were subjected to:
1- Full history taking including the cause of discontinuation
of methotrexate for those who stopped methotrexate.
2- Thorough clinical examination.
3- DAS 28 (including the number of swollen joints, number
of tender joints and ESR) was calculated for all patients.
4- Plain X-ray both hands to evaluate for juxta–articular
osteopenia and erosive disease.
5- Laboratory investigations including ESR, complete
blood count (CBC), Alanine aminotransferase (ALT),creatinine, Random blood sugar (RBS) and Rheuma-
toid factor (RF).
To identify factors which may be associated with increased
risk for methotrexate discontinuation, patients were recruited
into two groups for further statistical analysis:
1- Group 1: Those still using Methotrexate.
2- Group 2: Those stopped using Methotrexate.
The study has been approved by local ethics committee and
it conforms to the standards currently applied in Cairo Univer-
sity Teaching Hospitals.
Statistics: The data were coded and entered using the statis-
tical package SPSS version 15. The data were summarized
using descriptive statistics: mean ± standard deviation
(±SD), or frequencies (n) and percentages (%). Statistical dif-
ferences between groups were tested using Chi Square test (v2)
for qualitative variables, Independent sample t-test and ANO-
VA (analysis of variance) for quantitative normally distributed
variables and nonparametric Mann Whitney test and Kruskal
Wallis test for not normally distributed quantitative variables.
Correlations were done to test for linear relations between
variables. A probability value (P value) <0.05 was considered
statistically signiﬁcant.
3. Results
This study included 157 rheumatoid arthritis patients accord-
ing to the revised ACR classiﬁcation criteria for RA [10].
One hundred and thirty eight (87.9%) of our patients were fe-
males and 19 (12.1%) were males. Age ranged from 20 to
71 years with a mean of 46.77 ± 11.55, disease duration ran-
ged from 1 to 25 years with a mean of 7.77 ± 5.83.
Number of swollen joints in our patients ranged from 0 to
20 with a mean of 5.62 ± 4.27, while number of tender joints
in our patients ranged from 0 to 24 with a mean of
7.68 ± 4.79, Disease activity score for 28 joints (DAS 28)
[11] ranged from 2.2 to 7.8 with a mean of 5.19 ± 1.13.
RF was found to be positive in 140 (89.2%) of our cases,
juxta articular osteoporosis in X-ray hands was detected in
154 (98.1%), while radiological erosion detected in 114
(72.6%), subcutaneous nodule (past or current) was detected
in 52 (33.1%) of our patients. Laboratory features of our pa-
tients were shown in Table 1.
Sixty two (39.5%) of our patients were using methotrexate
as the only DMARD, 49 (31.2%) were using MTX and other
Table 4 Comparison between those on methotrexate and
those stopped methotrexate regarding NSAID use.
NSAID No NSAID Yes Total P value
MTX continue count 27 84 111 0.033
58.7% 75.7% 70.7%
MTX discontinue count 19 27 46
41.3% 24.3% 29.3%
46 111 157
100% 100% 100%
NSAID: Non steroidal anti inﬂammatory drugs.
Table 2 Causes of methotrexate (MTX) discontinuation.
Cause Frequency Percent
Afraid of side eﬀect 1 2.2
Poor compliance 3 6.5
Cancer Thyroid 1 2.2
Elevation of liver enzymes 2 4.3
Gastric upset (nausea, gastritis and peptic ulcer) 26 56.5
Discovered to be HCV positive 4 8.7
Leucopenia 1 2.2
Pneumonitis 1 2.2
Poor response 1 2.2
Planning for pregnancy 3 6.5
Unavailable 2 4.3
Chest tuberculosis 1 2.2
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including methotrexate, while one of them (0.6%) stopped
all DMARDS. On the other hand 111 (70.7%) of our patients
were using NSAIDS, while 91 (57.9%) were on steroids.
In the current study 46 (29.3%) of the patients stopped
MTX due to different causes which are shown in Table 2, while
Tables 3 and 4 show the comparison between the two groups.
4. Discussion
In the present study which included 157 RA patients with a
mean disease duration of 7.77 ± 5.83 years, 111 (70.7%) pa-
tients were currently on MTX, 62 (39.5%) on MTX alone
and 49 (31.2%) were on combination of MTX and other
DMARDS, while 46 (29.3%) of the patients stopped MTX
due to different causes. This result is in line with what was re-
ported regarding the rate of discontinuation of MTX which
was found to be 37% after about 6 years [12] and about
45% after 8 years [13], indicating that MTX is a safe andTable 3 Comparison between the two groups.
Still using MTX group 1
Mean ± SD
Age (years) 46.76 years ± 11.35
Weight (kilograms) 74.21 ± 15.86
Height (cm) 161.15 ± 7.63
Hemoglobin (g%) 11.69 ± 1.28
Platelet (thousands/mm3) 303.26 ± 80.86
Creatinine (mg/dl) 0.84 ± 0.24
ESR (mm/hour) 53.28 ± 22.88
TLC (thousands/mm3) 7.05 ± 2.29
ALT (U/L) 20.87 ± 19.28
Random blood sugar (mg/dl) 109.14 ± 40.12
Disease duration (years) 7.04 ± 5.58
SWJ 5.57 ± 4.07
TJ 7.75 ± 4.66
DGA 3.99 ± 2.14
Current steroid dose in mg/d 6.58 ± 2.73
Steroid cumulative dose in mg 6905.24 ± 11531.85
VAS 5.64 ± 2.33
DAS 28 5.27 ± 1.06
ESR: Erythrocyte sedimentation rate, TLC: Total leucocytic count, ALT:
count, DGA: Doctor global assessment, VAS: Visual analog scale, DASeffective medication [14] especially when comparing such rate
of discontinuation to what was reported regarding other
DMARDs in the ﬁrst 2 years, with discontinuation of about
80% of them due to adverse effect or lack of efﬁcacy [12].
Although well tolerated by most, some patients develop
important side effects such as cytopenias, gastrointestinal ad-
verse events (stomatitis, nausea), or abnormal liver function
tests, which may limit its use andmay result in additional health
care costs [3]. Among causes of discontinuation of MTX in our
patients gastric problems in the form of nausea and vomiting
and gastric discomfort were the most common representing
56.5%, while liver problems were the second cause representing
13% (8.7% found to be hepatitis C (HCV) reactive and 4.3%
due to elevation of liver enzymes), thus gastric problems and li-
ver problems together represent 69.5% of causes of discontinu-
ation of MTX in this group of Egyptian patients, and after
exclusion of the poor patient compliance, planning for preg-
nancy and poor availability of MTX sometimes, none of the
remaining causes of discontinuation exceeded 2.2%.
The high prevalence of hepatic and gastric adverse effects as
a cause of discontinuation of MTX among this group of Egyp-
tian patients could be explained in addition to the known Po-
tential liver toxicity of MTX [15], in part by the fact that
schistosomiasis is traditionally the most important publicStopped MTX group 2 P Signiﬁcance
Mean ± SD
46.80 ± 12.14 0.981 NS
72.28 ± 16.40 0.494 NS
159.37 ± 6.17 0.162 NS
11.92 ± 1.74 0.348 NS
307.57 ± 92.25 0.771 NS
0.79 ± 0.21 0.189 NS
44.37 ± 26.25 0. 030 Signiﬁcant
7.52 ± 2.74 0.326 NS
23.28 ± 32.15 0.942 NS
103.93 ± 23.36 0.994 NS
9.53 ± 6.10 0.007 Highly signiﬁcant
5.74 ± 4.77 0.891 NS
7.52 ± 5.13 0.659 NS
3.78 ± 2.15 0.532 NS
6.39 ± 3.55 0.435 NS
9522.17 ± 10224.76 0.004 Highly signiﬁcant
5.20 ± 2.32 0.354 NS
5.00 ± 1.27 0.203 NS
Alanine aminotransferase, SWJ: Swollen joint count, TJ: Tender joint
28: Disease activity score including 28 joints.
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major cause of liver disease in Egypt [16], furthermore HCV is
highly endemic [17], with the highest prevalence of adult HCV
infection in the world, affecting an average of 15–25% of the
population in rural communities [18]. On the other hand gas-
trointestinal (GI) adverse effects which include nausea, vomit-
ing, abdominal pain and diarrhea are common among MTX
treatment [19], as MTX is characterized by substantial upper
GI toxicity which in certain studies was found to be (32.2%)
[20], also it is well known that chronic disorders, such as rheu-
matic disorders, are associated with increased (GI) symptoms,
this may be due to the underlying conditions, however medica-
tions used such as NSAIDs, steroids and disease modifying
drugs have been associated with signiﬁcant GI adverse events
[21].
On comparing patients of group 1 (still using MTX) to pa-
tients of group 2 (stopped using MTX) we found highly signif-
icant statistical difference regarding disease duration
P= 0.007 and cumulative steroid dose P= 0.004 and signiﬁ-
cant statistical difference regarding ESR P= 0.03. Also by the
Chi square test signiﬁcant statistical difference was found
regarding NSAID use between those on MTX and those
who stopped MTX P= 0.03.
NSAIDs are among the most commonly prescribed group
of drugs, patients receiving NSAIDs often experience abdom-
inal discomfort, and some of them develop serious GI compli-
cations, such as ulceration, bleeding, perforation, or
obstruction [22]. Use of NSAIDs, including aspirin and selec-
tive cyclooxygenase (COX)-2 inhibitors may be associated with
a variety of changes, such as deﬁciency in prostaglandins, neu-
trophil activation, microcirculatory disturbances, oxygen free
radicals, and luminal acid, all contribute to the development
of NSAID-induced gastric injuries [23], also NSAID might
cause hepatic side effect [24], even it is now accepted to say that
NSAIDs, along with anti-infectious agents, list on the top for
causes of drug-induced liver injury. NSAIDs exhibit a broad
spectrum of liver damage ranging from asymptomatic, tran-
sient, hyper-transaminasemia to fulminant hepatic failure. In-
deed roughly 10% of total drug-induced hepatotoxicity is
NSAID related [25]. The above data indicate that NSAID
may play an important role in raising hepatic and gastric side
effects, both of them are the two most important causes of dis-
continuation of MTX in our patients.
The highly signiﬁcant statistical difference regarding cumu-
lative steroid dose P= 0.004 in the present study is in accor-
dance with what Filaretova and colleagues [26] reported as
they noted that one of the principles for minimizing the unde-
sirable side effects of glucocorticoid therapy is to keep treat-
ment as short as possible, since treatment lasting 5–7 days
shows fewer side effects and that glucocorticoid induced ulcer
symptoms appeared after much longer treatment. Longer
duration of therapy with higher doses and the use in patholog-
ical condition convert the physiological gastroprotective effect
of the steroid to proulcerogenic effect, thus long term steroid
therapy is associated with increased GIT side effects which is
the most important cause of MTX discontinuation in our
study. Also our results are in agreement with Kinder and
coworkers [27] as they found that patients who had adverse
reactions to methotrexate, (19%) were also on low-dose pred-
nisolone and (48%) were on NSAID.
The highly signiﬁcant statistical difference regarding disease
duration P= 0.007 between group 1 and 2 is in accordancewith Bulatovic´ et al. [19] as they stated that MTX-intolerant
patients had longer disease durations and received MTX for
longer periods than did MTX-tolerant patients. Also it is logic
that patients are relatively healthier early in the disease and
may be better able to tolerate possible side effects [8]. Pavelka
et al. [12] reported that about 80% of all DMARDs are discon-
tinued up to 2 years after beginning treatment owing to ad-
verse effects or lack of efﬁcacy and this duration is longer in
MTX and in such condition it is usually longer than 5 years,
also Pincus and coworker [28] reported that the rate of discon-
tinuation of traditional DMARDs increases with the duration
of therapy and that the tolerability of MTX is much better
than other DMARDs. The previous data indicate that the
duration of therapy is an important factor regarding the in-
crease in side effects and discontinuation which is in our opin-
ion due to the cumulative effect of disease, DMARDs, steroid
and NSAIDs on the body.
We do not have clear explanation regarding the signiﬁcant
difference of the ESR between group one and group two,
P= 0.03 and this is what was noted by Pavelka et al. [12] as
they found no signiﬁcant difference regarding the duration of
therapy with DMARD including MTX between those with ini-
tial high or low ESR. However another study showed that
Leﬂunomide, showed a signiﬁcant clinical and radiological
improvement compared with the standard MTX regimen in Ja-
pan and that DAS28-ESR improved much in the leﬂunomide
treated group than in the methotrexate treated group [29], indi-
cating that the lower ESR in the group which stopped MTX
may be a result of using more potent DMARDs or combina-
tion therapy in this group.
Finally we can say that MTX is a safe and effective drug on
the long run especially when compared to other DMARDs and
every attempt should be done to minimize gastric and hepatic
causes of discontinuation of MTX, in order to get the beneﬁts
of drug considered as the cornerstone in RA treatment. In our
opinion this could be achieved by the use of gastro protective
drugs mainly for patients on NSAID and glucocorticoid, and
by minimizing NSAID and glucocorticoid as much as we can
especially for patients with long disease duration, also the he-
patic side effect could be minimized by proper screening of the
patients for HCV and tight follow up of liver enzymes.
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